The current focus in autism spectrum disorders is Rett Syndrome. The appointment of Dr Horrigan, however, reinforces a growing perception that NNZ-2566 may have remarkable properties in addressing a wide range of 'neurodevelopmental disorders and head injuries.' A perception given some gravitas by Horrigan's remark in the company announcement;
"Neuren is uniquely situated to make a significant contribution to the delivery of better therapeutics for several rare and common CNS conditions that have a growing public health impact," said Horrigan.
just the beginning
-
- There are more pages in this discussion • 13 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$16.54 |
Change
-0.490(2.88%) |
Mkt cap ! $2.114B | |||
| Open | High | Low | Value | Volume |
| $16.94 | $17.02 | $16.38 | $10.33M | 620.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 5061 | $16.52 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $16.62 | 1284 | 1 |
View Market Depth
| Last trade - 16.10pm 13/11/2024 (20 minute delay) ? |
| NEU (ASX) Chart |